DDInter32 DDInter899
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Afatinib {u} (Compound) resembles {v} (Compound) Gefitinib
Afatinib {u} (Compound) binds {v} (Gene) ABCB1
Afatinib {u} (Compound) upregulates {v} (Gene) MTHFD2
Afatinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Afatinib {u} (Compound) downregulates {v} (Gene) IGFBP2
Afatinib {u} (Compound) causes {v} (Side Effect) Diarrhoea
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Afatinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Afatinib {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) ERBB2
Afatinib (Compound) resembles Gefitinib (Compound)
Afatinib (Compound) binds ABCB1 (Gene)
Afatinib (Compound) upregulates MTHFD2 (Gene)
Afatinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Afatinib (Compound) downregulates IGFBP2 (Gene)
Afatinib (Compound) causes Diarrhoea (Side Effect)
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Afatinib may lead to a major life threatening interaction when taken with Lomitapide
Afatinib (Compound) binds ERBB2 (Gene) and Afatinib (Compound) downregulates ERBB2 (Gene)